JMP Securities Keeps Market Outperform Rating on Sana Biotechnology (SANA)

Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the Top 10 Stocks Under $10 That Could Triple. On August 21, JMP Securities reaffirmed its Market Outperform rating for Sana Biotechnology, Inc. (NASDAQ:SANA) with a price target of $5.

This decision came after Sana Biotechnology, Inc. (NASDAQ:SANA) shared financial results and updates for the second quarter of 2025.

The research firm highlighted the six-month clinical results from the company’s ongoing UP421 study for type 1 diabetes (T1D) as the most important recent news.

JMP analysts pointed out that the modified pancreatic islet cell program is validating Sana Biotechnology, Inc.’s (NASDAQ:SANA) HIP platform for treating type 1 diabetes.

The firm also highlighted that the company’s iPSC program is advancing and the company plans to submit an IND filing in 2026. JMP analysts also pointed to another key catalyst for the company, the upcoming SC291 data for autoimmune disease (AID) expected in Q4 2025.

Sana Biotechnology, Inc. (NASDAQ:SANA) reported a pro forma Q2 2025 cash position of $177.2 million. JMP analysts noted that this is enough to support the company’s ongoing research and development efforts.

Sana Biotechnology, Inc. (NASDAQ:SANA) is a biotechnology company focused on developing and delivering engineered cells as a new class of medicines.

While we acknowledge the potential of SANA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Hot Mid Cap Stocks to Buy Now and 10 Best Affordable Stocks Under $50 to Buy.

Disclosure: None. This article is originally published at Insider Monkey.